US/UK/Canada

Share

Pick a time period -

Observe Medical ASA – Minutes from Annual General Meeting

Observe Medical ASA has today, June 3, 2022, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact:  Rune Nystad, CEO Observe MedicalMobile: +47 916 24 683E-mail: rune.nystad@observemedical.com Per Arne Nygård, CFO of Observe MedicalMobile: +47 411 04 345E-mail: perarne.nygard@observemedical.com This information is subject of the disclosure

Observe Medical ASA: Business update and first quarter 2022 presentation

Oslo, 3 June 2022 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) today releases its first quarter results for 2022. Observe Medical has made progress across its medtech platform during the quarter, preparing and strengthening it for growth. The Company has also streamlined the organization and other operational synergies following the acquisition of Biim Ultrasound in January this year. Observe Medical has continued the roll-out of Biim, a patented, wireless, and pocketable ultrasound probe, across Fresenius Kidney Care’s educational centres throughout the US.

Observe Medical ASA: Invitation to business update and first quarter 2022 presentation

Oslo, 2 June 2022 – Observe Medical ASA (OSE: OBSRV) ("Observe Medical"or the "Company"), will release its first quarter results for 2022 on Friday, 3 June 2022. The presentation will be available on Newsweb and the Company’s website at 07:00 CET. Following the release, CEO, Rune Nystad and CFO, Per Arne Nygård will host a brief business update at Haakon VIIs gate 2, starting at 08:30 CET. The live presentation will also be available via webcast at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20220603_1/  After the live event, the presentation and

Observe Medical ASA: Notice of Annual General Meeting

Oslo, May 13, 2022 – Observe Medical ASA (OSE:OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, June 3 2022 at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gate 2, 0161 Oslo for those attending in person and via Lumi for those attending digitally. Voting will be carried out electronically via Lumi both for shareholders attending in person and attending digitally. It is also possible to vote in advance or give proxy.  The Notice of the Annual General Meeting is attached. The Notice is posted electronically or by mail to all

Observe Medical Annual Report for 2021

Oslo, 29 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2021, which was approved by the board of directors on 28 April 2022. "It has been a transformational start to 2022, so I would like to take this opportunity to focus on the way forward. We have a strong portfolio of proprietary medtech products available globally, an international and dedicated team, and the drive to succeed. We have an exciting road ahead, and I look forward to embarking on this journey alongside our dedicated and highly

Observe Medical successfully delivers ultrasound probes to all of Fresenius Kidney Care’s educational centers in the USA

Oslo, 28 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that it has delivered an additional 58 Biim ultrasound probes to Fresenius Kidney Care in the US, completing the delivery of a total of 260 ultrasound probes in the first phase of the delivery to Fresenius Kidney Care as planned. As part of the partnership agreement announced in January this year, Observe Medical has delivered the final batch of Biim ultrasound probes to the educational centers of Fresenius Kidney Care, a leading provider of kidney care services in the US. The educational

Observe Medical receives MDR certification under the new European Medical Device Regulation

Oslo, April 1, 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Sippi® Disposable Unit has received Medical Device Regulation Certification, ensuring continued market access for the unit in Europe after 2024.  Rune Nystad, CEO of Observe Medical, commented: "The MDR Certification confirms that the Sippi® Disposable Unit is compliant with the latest requirements for medical devices in Europe. This is important as it demonstrates our commitment not only to adhere to the latest regulatory compliance but also to ensuring our clients that we deliver

Observe Medical ASA: Business update and interim financial results for the fourth quarter and full year 2021

Oslo, 29 March 2022 – Observe Medical ASA (“the Company” or “Observe Medical”) today releases a combined business update and interim financial results for the fourth quarter and full year 2021. Observe Medical can also report that 202 out of 260 Biim ultrasound probes have been successfully shipped. Another 58 Biim probes will be delivered in April this year, completing the planned initial delivery of Biim probes to Fresenius Kidney Care’s 260 educational dialysis clinics in the US. Fresenius is the leading provider of kidney care services in the US. “For Observe Medical, this marks a

Rune Nystad appointed CEO of Observe Medical ASA

The Board of Directors has today appointed Rune Nystad as Chief Executive Officer (CEO) of Observe Medical ASA  (the “Company” or “Observe Medical”), a Nordic medtech company with global reach. He succeeds Björn Larsson, who has headed the Company since 2019. Rune Nystad was previously the CEO of Biim Ultrasound, a company recently acquired by Observe Medical. Nystad has broad experience from the US medtech industry, of which seven years in Boston Scientific. The change of leadership is effective today and Rune Nystad will present at the Company’s Business update and Q4 presentation

Observe Medical ASA: Invitation to business update and fourth quarter 2021 financial presentation

Oslo, March 28, 2022 - Observe Medical ASA (OSE: OBSRV) ("Observe Medical" or the "Company"), will be announcing its fourth quarter 2021 results on Tuesday 29 March 2022. Members of the Management team will host a presentation at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. The live webcast will be available at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20220329_1/ After the live event, the presentation and recording will be made available under the Investor Relations section on the Company's website,  https://observemedical.com/

Disclosure of large shareholding

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by JPB AS. Reference is made to Observe Medical ASA's (the "Company") stock exchange announcement on 10 March 2022 regarding the registration of the share capital increase  pertaining to the 8,171,913 new shares in the Company with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), issued as partial consideration to the sellers of Biim Ultrasound AS (the "Consideration Shares"). Following the registration of the share capital increase pertaining to the Consideration Shares, the

Observe Medical ASA - Registration of share capital increase

Oslo, 10 March 2022: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 8 March 2022 regarding the Company's completion of the acquisition of Biim Ultrasound AS and the issuance of 8,171,913 new shares in the Company as partial consideration to the sellers of Biim Ultrasound AS (the "Consideration Shares"). The share capital increase pertaining to the Consideration Shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 13,907,830.56, divided on 53,491,656 shares,

Observe Medical completes acquisition of Biim Ultrasound and issues consideration shares

Oslo, 8 March 2022: Observe Medical ASA (OSE: OBSRV) (the "Company" or Observe Medical") is excited to announce the completion of the acquisition of Biim Ultrasound AS ("Biim Ultrasound"), an international medical ultrasound technology company, adding another innovative product that improves patient welfare and outcome and that promotes positive health economics to its portfolio. With this acquisition, Observe Medical also significantly strengthens and broadens its distribution network into the US. This combined expansion of product range and distribution capacity are important steps

Observe Medical ASA – Registration of share capital increase pertaining to the rights issue

7 March 2022: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company ") on 24 February 2022, regarding the final result of the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per Offer Share (the "Rights Issue"). The share capital increase pertaining to the Rights Issue has now been registered in the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's new share capital is NOK 11,783,133.18 divided into 45,319,743 shares, each with a nominal value of

Observe Medical ASA – Subscription and allocation of offer shares in the rights issue to by a primary insider and a close associate of a primary insider

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 21 February 2022, regarding the exercise of subscription rights in the rights issue by certain primary insiders and a close associate of a primary insider, and today, on 24 February 2022 regarding the final results of the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per share (the "Rights Issue"). Ingerø Reiten Investment Company AS ("IRIC"), a closely associated person of Terje Bakken, chairman of the board of

Observe Medical ASA – Final results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 23 February 2022 regarding the preliminary results in the rights issue of 25,714,286 new shares in the Company (

Observe Medical ASA – Preliminary results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022 regarding the commencement of the subscription period in the rights issue of 25,714,286 new

Observe Medical ASA – The subscription period for the rights issue expires today

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022 regarding the commencement of the subscription period in the rights issue of 25,714,286 new

Observe Medical ASA – Exercise of subscription rights in the rights issue by a primary insider and a close associate of a primary insider

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld, Board member of Observe Medical ASA has today, on 22 February 2022, exercised 14,000 subscription rights in the Rights Issue, entitling Thomas Grunfeld to be allocated 14,000 offer shares in the Rights Issue at a price per offer share of NOK 7.00,

Observe Medical ASA - Disclosure of large shareholding

Mandatory disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act by Navamedic ASA. Reference is made to the previous stock exchange announcements from Observe Medical ASA (the "Company") announcing a fully underwritten rights issue of 25,714,286 new shares in the Company, raising gross proceeds of approximately NOK 180 million (the "Rights Issue"). In the Rights Issue, each existing shareholder of the Company as of 4 February 2022 (and being registered as such in Euronext Securities Oslo, the Norwegian Central Securities Depository (the "VPS") as at the expiry of 8

Observe Medical ASA - Sale of subscription rights in the rights issue by a close associate of a primary insider

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. Navamedic ASA, a closely associated person of Terje Bakken, chairman of the board of directors of Observe Medical ASA, has today, on 21 February 2022, sold 4,506,500 subscription rights in the Rights Issue of their total

Observe Medical ASA – Acquisition of subscription rights in the rights issue by a primary insider and a close associate of a primary insider

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue of 25,714,286 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7.00 per offer share (the "Rights Issue"). Thomas Grunfeld, board member of Observe Medical ASA has purchased 14,000 subscription rights in the Rights Issue, which upon exercise will entitle Thomas Grunfeld to be allocated 14,000 Offer Shares in the Rights Issue at a price per Offer Share of NOK 7.00,

Observe Medical ASA – Exercise of subscription rights in the rights issue by primary insiders and a close associate of a primary insider

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company. Ingerø Reiten Investment Company AS, a closely associated person of Terje Bakken, chairman of the board of directors of Observe Medical ASA, has today, on 21 February 2022, exercised 5,166,861 subscription rights in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe